Pub Date : 2023-12-01Epub Date: 2023-08-12DOI: 10.37201/req/032.2023
A Téllez Santoyo, C Lopera, A Ladino Vásquez, F Seguí Fernández, I Grafiá Pérez, M Chumbita, T F Aiello, P Monzó, O Peyrony, P Puerta-Alcalde, C Cardozo, N Garcia-Pouton, P Castro, S Fernández Méndez, J M Nicolas Arfelis, A Soriano, C Garcia-Vidal
Objective: Clinical data on which artificial intelligence (AI) algorithms are trained and tested provide the basis to improve diagnosis or treatment of infectious diseases (ID). We aimed to identify important data for ID research to prioritise efforts being undertaken in AI programmes.
Methods: We searched for 1,000 articlesfrom high-impact ID journals on PubMed, selecting 288 of the latest articles from 10 top journals. We classified them into structured or unstructured data. Variables were homogenised and grouped into the following categories: epidemiology, admission, demographics, comorbidities, clinical manifestations, laboratory, microbiology, other diagnoses, treatment, outcomes and other non-categorizable variables.
Results: 4,488 individual variables were collected, from the 288 articles. 3,670 (81.8%) variables were classified as structured data whilst 818 (18.2%) as unstructured data. From the structured data, 2,319 (63.2%) variables were classified as direct-retrievable from electronic health records-whilst 1,351 (36.8%) were indirect. The most frequent unstructured data were related to clinical manifestations and were repeated across articles. Data on demographics, comorbidities and microbiology constituted the most frequent group of variables.
Conclusions: This article identified that structured variables have comprised the most important data in research to generate knowledge in the field of ID. Extracting these data should be a priority when a medical centre intends to start an AI programme for ID. We also documented that the most important unstructured data in this field are those related to clinical manifestations. Such data could easily undergo some structuring with the use of semi-structured medical records focusing on a few symptoms.
{"title":"Identifying the most important data for research in the field of infectious diseases: thinking on the basis of artificial intelligence.","authors":"A Téllez Santoyo, C Lopera, A Ladino Vásquez, F Seguí Fernández, I Grafiá Pérez, M Chumbita, T F Aiello, P Monzó, O Peyrony, P Puerta-Alcalde, C Cardozo, N Garcia-Pouton, P Castro, S Fernández Méndez, J M Nicolas Arfelis, A Soriano, C Garcia-Vidal","doi":"10.37201/req/032.2023","DOIUrl":"10.37201/req/032.2023","url":null,"abstract":"<p><strong>Objective: </strong>Clinical data on which artificial intelligence (AI) algorithms are trained and tested provide the basis to improve diagnosis or treatment of infectious diseases (ID). We aimed to identify important data for ID research to prioritise efforts being undertaken in AI programmes.</p><p><strong>Methods: </strong>We searched for 1,000 articlesfrom high-impact ID journals on PubMed, selecting 288 of the latest articles from 10 top journals. We classified them into structured or unstructured data. Variables were homogenised and grouped into the following categories: epidemiology, admission, demographics, comorbidities, clinical manifestations, laboratory, microbiology, other diagnoses, treatment, outcomes and other non-categorizable variables.</p><p><strong>Results: </strong>4,488 individual variables were collected, from the 288 articles. 3,670 (81.8%) variables were classified as structured data whilst 818 (18.2%) as unstructured data. From the structured data, 2,319 (63.2%) variables were classified as direct-retrievable from electronic health records-whilst 1,351 (36.8%) were indirect. The most frequent unstructured data were related to clinical manifestations and were repeated across articles. Data on demographics, comorbidities and microbiology constituted the most frequent group of variables.</p><p><strong>Conclusions: </strong>This article identified that structured variables have comprised the most important data in research to generate knowledge in the field of ID. Extracting these data should be a priority when a medical centre intends to start an AI programme for ID. We also documented that the most important unstructured data in this field are those related to clinical manifestations. Such data could easily undergo some structuring with the use of semi-structured medical records focusing on a few symptoms.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9990444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2023-09-18DOI: 10.37201/req/058.2023
A Maldonado-Barrueco, C Sanz-González, I Falces-Romero, P García-Clemente, J Cacho-Calvo, I Quiles-Melero
Objective: The prevalence of drug-resistant Neisseria gonorrhoeae (NG) infections is increasing. Studies report the prevalence of NG strains presenting A2059G/C2611T (rRNA23S) and S91F (parC) mutations conferring resistance to azithromycin and ciprofloxacin.
Methods: We conducted a prospective cohort study evaluating first void-urine urines, rectal, and oropharyngeal swabs collected from a cohort of patients in a tertiary hospital in Madrid between October 2022 and January 2023. Samples were screened by Allplex 7-STI Essential Assay (Seegene). Drug resistances were performed by Allplex NG-DR Assay (Seegene).
Results: A total of 1,415 patients were included, of which 112 had a positive sample for NG infection. One patient had a C2611T mutation (0.9%) and neither patient showed A2059G mutation. We found 67 (59.8%) S91F-positive patients. Forty-four patients (39.3%) not had any mutations.
Conclusions: We report a low-prevalence of mutations A2059G/C2611T to macrolides and a high-prevalence to S91F in NG infections. Molecular methods for the detection of NG resistance could be useful in direct non-culturable samples.
{"title":"Prevalence of mutations associated with macrolide and fluoroquinolone resistance in Neisseria gonorrhoeae with Allplex NG-DR Assay (Seegene) in a tertiary hospital from Madrid, Spain.","authors":"A Maldonado-Barrueco, C Sanz-González, I Falces-Romero, P García-Clemente, J Cacho-Calvo, I Quiles-Melero","doi":"10.37201/req/058.2023","DOIUrl":"10.37201/req/058.2023","url":null,"abstract":"<p><strong>Objective: </strong>The prevalence of drug-resistant Neisseria gonorrhoeae (NG) infections is increasing. Studies report the prevalence of NG strains presenting A2059G/C2611T (rRNA23S) and S91F (parC) mutations conferring resistance to azithromycin and ciprofloxacin.</p><p><strong>Methods: </strong>We conducted a prospective cohort study evaluating first void-urine urines, rectal, and oropharyngeal swabs collected from a cohort of patients in a tertiary hospital in Madrid between October 2022 and January 2023. Samples were screened by Allplex 7-STI Essential Assay (Seegene). Drug resistances were performed by Allplex NG-DR Assay (Seegene).</p><p><strong>Results: </strong>A total of 1,415 patients were included, of which 112 had a positive sample for NG infection. One patient had a C2611T mutation (0.9%) and neither patient showed A2059G mutation. We found 67 (59.8%) S91F-positive patients. Forty-four patients (39.3%) not had any mutations.</p><p><strong>Conclusions: </strong>We report a low-prevalence of mutations A2059G/C2611T to macrolides and a high-prevalence to S91F in NG infections. Molecular methods for the detection of NG resistance could be useful in direct non-culturable samples.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10653474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2023-09-08DOI: 10.37201/req/085.2023
C Borralleras, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, J M Eiros, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, M Fernández-Prada, A Gil de Miguel, G Mirada Masip, F Moraga-Llop, D Ocaña Rodríguez, J Puig-Barberà, J Vázquez, J Vergara-Alert, S de Cambra
{"title":"Update on Bimervax® immunogenicity amplitude. Insights on humoral response against XBB.1.5 from an extension study (NTC05142553).","authors":"C Borralleras, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, J M Eiros, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, M Fernández-Prada, A Gil de Miguel, G Mirada Masip, F Moraga-Llop, D Ocaña Rodríguez, J Puig-Barberà, J Vázquez, J Vergara-Alert, S de Cambra","doi":"10.37201/req/085.2023","DOIUrl":"10.37201/req/085.2023","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10161794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01Epub Date: 2023-06-07DOI: 10.37201/req/137.2022
E Herranz-Bayo, R Huarte-Lacunza, A Pinilla-Rello, I Aguiló-Lafarga, A I López-Calleja
Objective: In 2019, the European Committee for the Study of Antibiotic Susceptibility modified the categories of antibiotic susceptibility tests to include the term "susceptible with increased exposure". Following the dissemination of local protocols reflecting these modifications, the aim of our study was to analyse whether prescribers have adapted to them and the clinical impact in cases of inadequacy.
Methods: Observational and retrospective study of patients with infection who received antipseudomonal antibiotics from January to October 2021 in a tertiary hospital.
Results: Non-adherence to the guideline recommendations was 57.6% in the ward and 40.4% in the ICU (p<0.05). In both the ward and ICU, the group with the most prescriptions not by the guideline recommendations were aminoglycosides (92.9% and 64.9% respectively) for using suboptimal doses, followed by carbapenems (89.1% and 53.7% respectively) for not administering an extended infusion. On the ward, the mortality rate during admission or at 30 days in the inadequate therapy group was 23.3% vs 11.5% in those who received adequate treatment (OR: 2.34; 95% CI 1.14-4.82); in ICU there were no statistically significant differences.
Conclusions: The results show the need to implement measures to ensure better dissemination and knowledge of key concepts in antibiotic management, to ensure increased exposures, and to be able to provide better infection coverage, as well as to avoid amplifying resistant strains.
{"title":"[Adequacy of the consumption of antipseudomonal antibiotics after changes in the 2019 EUCAST criteria].","authors":"E Herranz-Bayo, R Huarte-Lacunza, A Pinilla-Rello, I Aguiló-Lafarga, A I López-Calleja","doi":"10.37201/req/137.2022","DOIUrl":"10.37201/req/137.2022","url":null,"abstract":"<p><strong>Objective: </strong>In 2019, the European Committee for the Study of Antibiotic Susceptibility modified the categories of antibiotic susceptibility tests to include the term \"susceptible with increased exposure\". Following the dissemination of local protocols reflecting these modifications, the aim of our study was to analyse whether prescribers have adapted to them and the clinical impact in cases of inadequacy.</p><p><strong>Methods: </strong>Observational and retrospective study of patients with infection who received antipseudomonal antibiotics from January to October 2021 in a tertiary hospital.</p><p><strong>Results: </strong>Non-adherence to the guideline recommendations was 57.6% in the ward and 40.4% in the ICU (p<0.05). In both the ward and ICU, the group with the most prescriptions not by the guideline recommendations were aminoglycosides (92.9% and 64.9% respectively) for using suboptimal doses, followed by carbapenems (89.1% and 53.7% respectively) for not administering an extended infusion. On the ward, the mortality rate during admission or at 30 days in the inadequate therapy group was 23.3% vs 11.5% in those who received adequate treatment (OR: 2.34; 95% CI 1.14-4.82); in ICU there were no statistically significant differences.</p><p><strong>Conclusions: </strong>The results show the need to implement measures to ensure better dissemination and knowledge of key concepts in antibiotic management, to ensure increased exposures, and to be able to provide better infection coverage, as well as to avoid amplifying resistant strains.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/02/revespquimioter-36-470.PMC10586739.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9590032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01Epub Date: 2023-06-19DOI: 10.37201/req/038.2023
J Del Romero, S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, J Gómez Castellá, M Palomo, R García Berrio, A Couso González, C Sotomayor, E Bouza
Sexually Transmitted Infections (STI) are a major public health problem. The problems inherent to their diagnosis, treatment and prevention have to do not only with their nature, but also with organizational issues and overlapping competencies of the different health authorities in Spain. The real situation of STI in Spain, at present, is poorly known. For this reason, the Scientific Committee on COVID and Emerging Pathogens of the Illustrious Official College of Physicians of Madrid (ICOMEM) has formulated a series of questions on this subject which were distributed, not only among the members of the Committee, but also among experts outside it. The central health authorities provide very high and increasing figures for gonococcal infection, syphilis, Chlamydia trachomatis infection and lymphogranuloma venereum (LGV). Both HIV infection and Monkeypox are two important STI caused by viruses in our environment, to which it should be added, mainly, Herpes simplex virus (HSV) and Human papillomavirus (HPV) infections. Emerging microorganisms such as Mycoplasma genitalium pose not only pathogenic challenges but also therapeutic problems, as in the case of N. gonohrroeae. The pathways that patients with suspected STI follow until they are adequately diagnosed and treated are not well known in Spain. Experts understand that this problem is fundamentally managed in public health institutions, and that Primary Care and Hospital Emergency Services, together with some institutions that deal monographically with this problem, are the recipients of most of these patients. One of the most serious difficulties of STI lies in the availability of the microbiological tests necessary for their diagnosis, particularly in this era of outsourcing of microbiology services. Added to this is the increased cost of implementing the latest generation of molecular techniques and the difficulties of transporting samples. It is clear that STI are not diseases to which the entire population is equally exposed and it is necessary to have a better knowledge of the risk groups where to focus the necessary interventions adapted to their characteristics. It should not be forgotten that STI are also a problem in the pediatric age group and that their presence can be a marker of sexual abuse with all that this implies in terms of health care and medicolegal activity. Finally, STI are infections that are associated with a high cost of care for which we have very little information. The possibility of expanding the automatic performance of laboratory tests for STI surveillance through laboratory routines is encountering ethical and legal problems that are not always easy to solve. Spain has created a ministerial area of specific attention to STI and there are plans to improve the diagnosis, treatment and prevention of these problems, but we still lack the necessary evidence on their impact. We cannot forget that these are diseases that transcend the individual and constitute a Pu
{"title":"Sexually transmitted infections in Spain: Current status.","authors":"J Del Romero, S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, J Gómez Castellá, M Palomo, R García Berrio, A Couso González, C Sotomayor, E Bouza","doi":"10.37201/req/038.2023","DOIUrl":"10.37201/req/038.2023","url":null,"abstract":"<p><p>Sexually Transmitted Infections (STI) are a major public health problem. The problems inherent to their diagnosis, treatment and prevention have to do not only with their nature, but also with organizational issues and overlapping competencies of the different health authorities in Spain. The real situation of STI in Spain, at present, is poorly known. For this reason, the Scientific Committee on COVID and Emerging Pathogens of the Illustrious Official College of Physicians of Madrid (ICOMEM) has formulated a series of questions on this subject which were distributed, not only among the members of the Committee, but also among experts outside it. The central health authorities provide very high and increasing figures for gonococcal infection, syphilis, Chlamydia trachomatis infection and lymphogranuloma venereum (LGV). Both HIV infection and Monkeypox are two important STI caused by viruses in our environment, to which it should be added, mainly, Herpes simplex virus (HSV) and Human papillomavirus (HPV) infections. Emerging microorganisms such as Mycoplasma genitalium pose not only pathogenic challenges but also therapeutic problems, as in the case of N. gonohrroeae. The pathways that patients with suspected STI follow until they are adequately diagnosed and treated are not well known in Spain. Experts understand that this problem is fundamentally managed in public health institutions, and that Primary Care and Hospital Emergency Services, together with some institutions that deal monographically with this problem, are the recipients of most of these patients. One of the most serious difficulties of STI lies in the availability of the microbiological tests necessary for their diagnosis, particularly in this era of outsourcing of microbiology services. Added to this is the increased cost of implementing the latest generation of molecular techniques and the difficulties of transporting samples. It is clear that STI are not diseases to which the entire population is equally exposed and it is necessary to have a better knowledge of the risk groups where to focus the necessary interventions adapted to their characteristics. It should not be forgotten that STI are also a problem in the pediatric age group and that their presence can be a marker of sexual abuse with all that this implies in terms of health care and medicolegal activity. Finally, STI are infections that are associated with a high cost of care for which we have very little information. The possibility of expanding the automatic performance of laboratory tests for STI surveillance through laboratory routines is encountering ethical and legal problems that are not always easy to solve. Spain has created a ministerial area of specific attention to STI and there are plans to improve the diagnosis, treatment and prevention of these problems, but we still lack the necessary evidence on their impact. We cannot forget that these are diseases that transcend the individual and constitute a Pu","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/10/revespquimioter-36-444.PMC10586737.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01Epub Date: 2023-06-12DOI: 10.37201/req/046.2023
C Borralleras, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, J M Eiros, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, M Fernández-Prada, A Gil de Miguel, G Mirada Masip, F Moraga-Llop, D Ocaña Rodríguez, J Puig-Barberà, J Vázquez, J Vergara-Alert, S de Cambra
Objective: Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection from infection in addition to protection from severe illness and hospitalisation. Here we present a review of the evidence base for a new COVID-19 vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U), and the results of an expert consensus.
Methods: The expert committee consisted of Spanish experts in medicine, family medicine, paediatrics, immunology, microbiology, nursing, and veterinary medicine. Consensus was achieved using a 4-phase process consisting of a face-to-face meeting during which the scientific evidence base was reviewed, an online questionnaire to elicit opinions on the value of PHH-1V, a second face-to-face update meeting to discuss the evolution of the epidemiological situation, vaccine programmes and the scientific evidence for PHH-1V and a final face-to-face meeting at which consensus was achieved.
Results: The experts agreed that PHH-1V constitutes a valuable novel vaccine for the development of vaccination programmes aimed towards protecting the population from SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and emerging SARS-CoV-2 variants, a potent immunological response, and a good safety profile. The physicochemical properties of the PHH-1V formulation facilitate handling and storage appropriate for global uptake.
Conclusions: The physicochemical properties, formulation, immunogenicity and low reactogenic profile of PHH-1V confirm the appropriateness of this new COVID-19 vaccine.
目标:随着我们从大流行阶段进入流行阶段,接种SARS-CoV-2疫苗对于减轻冠状病毒疾病(新冠肺炎)对个人、社会和全球的影响至关重要。现在需要的疫苗除了能预防重症和住院外,还能提供广泛、持久的免疫保护,防止感染。在这里,我们对新的新冠肺炎疫苗PHH-1V(Bimervax®;HIPRA HUMAN HEALTH S.L.U)的证据基础以及专家共识的结果进行了审查。方法:专家委员会由西班牙医学、家庭医学、儿科、免疫学、微生物学、护理和兽医专家组成。通过四个阶段的过程达成共识,其中包括一次面对面会议,审查科学证据库,一份在线问卷,征求对PHH-1V价值的意见,第二次面对面更新会议,讨论流行病学状况的演变,疫苗计划和PHH-1V的科学证据,以及达成共识的最后一次面对面会议。结果:专家们一致认为,PHH-1V是一种有价值的新型疫苗,可用于制定旨在保护人群免受严重急性呼吸系统综合征冠状病毒2型感染和疾病的疫苗接种计划。共识是基于对已建立和新出现的严重急性呼吸系统综合征冠状病毒2型变种的广谱疗效、有效的免疫反应和良好的安全性的证据。PHH-1V制剂的物理化学性质便于处理和储存,适合全球吸收。结论:PHH-1V的理化性质、配方、免疫原性和低反应原性证明了该新型新冠肺炎疫苗的适宜性。
{"title":"The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.","authors":"C Borralleras, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, J M Eiros, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, M Fernández-Prada, A Gil de Miguel, G Mirada Masip, F Moraga-Llop, D Ocaña Rodríguez, J Puig-Barberà, J Vázquez, J Vergara-Alert, S de Cambra","doi":"10.37201/req/046.2023","DOIUrl":"10.37201/req/046.2023","url":null,"abstract":"<p><strong>Objective: </strong>Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection from infection in addition to protection from severe illness and hospitalisation. Here we present a review of the evidence base for a new COVID-19 vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U), and the results of an expert consensus.</p><p><strong>Methods: </strong>The expert committee consisted of Spanish experts in medicine, family medicine, paediatrics, immunology, microbiology, nursing, and veterinary medicine. Consensus was achieved using a 4-phase process consisting of a face-to-face meeting during which the scientific evidence base was reviewed, an online questionnaire to elicit opinions on the value of PHH-1V, a second face-to-face update meeting to discuss the evolution of the epidemiological situation, vaccine programmes and the scientific evidence for PHH-1V and a final face-to-face meeting at which consensus was achieved.</p><p><strong>Results: </strong>The experts agreed that PHH-1V constitutes a valuable novel vaccine for the development of vaccination programmes aimed towards protecting the population from SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and emerging SARS-CoV-2 variants, a potent immunological response, and a good safety profile. The physicochemical properties of the PHH-1V formulation facilitate handling and storage appropriate for global uptake.</p><p><strong>Conclusions: </strong>The physicochemical properties, formulation, immunogenicity and low reactogenic profile of PHH-1V confirm the appropriateness of this new COVID-19 vaccine.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/52/revespquimioter-36-507.PMC10586735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01Epub Date: 2023-07-19DOI: 10.37201/req/041.2023
J Reina, C Iglesias
{"title":"[Detection of co-infection by Herpes simplex virus type 1 and type 2 in female genital ulcers].","authors":"J Reina, C Iglesias","doi":"10.37201/req/041.2023","DOIUrl":"10.37201/req/041.2023","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/47/revespquimioter-36-547.PMC10586738.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10190075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01Epub Date: 2023-07-17DOI: 10.37201/req/019.2023
T Herrero, M I Sanjoaquin, M Lafuente, A E Monje-López, L M Cabrera, M Betrán, A M Camón
Objective: The main objective of our investigation was to know the incidence and epidemiology of non-tuberculous mycobacteria (NTM) in our area and the prevalence of comorbidities in patients with MNT infection. As secondary objectives, we studied the distribution by species of MNT, the forms of disease and the type of sample used for its diagnosis.
Methods: A retrospective study was carried out in which all the isolates of mycobacteria carried out by the microbiology laboratory of the Hospital Clínico Universitario Lozano Blesa of Zaragoza during the period between January 1, 2011 and December 31, 2018 were included.
Results: A total of 533 mycobacteria were isolated, of which 295 (55.35%) were tuberculosis (MTB) and 238 (44.65%) were MNT. Of the whole MNT isolates, only 15.54% were considered clinically significant. Twenty-one species were identified being the most frequent: M. gordonae (26.89%), M. fortuitum (19.75%) and M. avium (16.39%). 32.72% of the MNT isolates were found in people over 70 years of age.
Conclusions: We can confirm that the reported number of MNT isolates in our area is higher than in previous periods. MNT infection is more common in men and those older than 70 years. The epidemiology, especially the risk factors, of MNT disease is changing.
{"title":"[Analysis of the incidence and epidemiology of non-tuberculous mycobacterial infections in the health area III of Aragón].","authors":"T Herrero, M I Sanjoaquin, M Lafuente, A E Monje-López, L M Cabrera, M Betrán, A M Camón","doi":"10.37201/req/019.2023","DOIUrl":"10.37201/req/019.2023","url":null,"abstract":"<p><strong>Objective: </strong>The main objective of our investigation was to know the incidence and epidemiology of non-tuberculous mycobacteria (NTM) in our area and the prevalence of comorbidities in patients with MNT infection. As secondary objectives, we studied the distribution by species of MNT, the forms of disease and the type of sample used for its diagnosis.</p><p><strong>Methods: </strong>A retrospective study was carried out in which all the isolates of mycobacteria carried out by the microbiology laboratory of the Hospital Clínico Universitario Lozano Blesa of Zaragoza during the period between January 1, 2011 and December 31, 2018 were included.</p><p><strong>Results: </strong>A total of 533 mycobacteria were isolated, of which 295 (55.35%) were tuberculosis (MTB) and 238 (44.65%) were MNT. Of the whole MNT isolates, only 15.54% were considered clinically significant. Twenty-one species were identified being the most frequent: M. gordonae (26.89%), M. fortuitum (19.75%) and M. avium (16.39%). 32.72% of the MNT isolates were found in people over 70 years of age.</p><p><strong>Conclusions: </strong>We can confirm that the reported number of MNT isolates in our area is higher than in previous periods. MNT infection is more common in men and those older than 70 years. The epidemiology, especially the risk factors, of MNT disease is changing.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/fa/revespquimioter-36-492.PMC10586744.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9826958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01Epub Date: 2023-07-18DOI: 10.37201/req/126.2022
A Mastroianni, V Vangeli, M V Mauro, R Manfredi, S Greco
{"title":"Turicella otitidis central venous-related bacteremia during pediatric acute lymphoblastic leukemia.","authors":"A Mastroianni, V Vangeli, M V Mauro, R Manfredi, S Greco","doi":"10.37201/req/126.2022","DOIUrl":"10.37201/req/126.2022","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/97/revespquimioter-36-531.PMC10586741.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9830557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01Epub Date: 2023-06-28DOI: 10.37201/req/070.2023
M Martínez-Sellés, F J Martín Sánchez, S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, J M Molero García, B Santiago, J A Caminero, C Barros, D García de Viedma, C Martín, E Bouza
We address the advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in the current epidemiological situation in Spain and after the declaration of the World Health Organization on May 5, 2023 of the end of COVID-19 as public health emergency. We advocate for prudence and flexibility, respecting the individual decision to wear a mask and emphasizing the need for its use when symptoms suggestive of a respiratory infection appear, in situations of special vulnerability (such as immunosuppression), or when caring for patients with those infections. At present, given the observed low risk of severe COVID-19 and the low transmission of other respiratory infections, we believe that it is disproportionate to maintain the mandatory use of masks in a general way in health centers and nursing homes. However, this could change depending on the results of epidemiological surveillance and it would be necessary to reconsider returning to the obligation in periods with a high incidence of respiratory infections.
{"title":"Advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in Spain. How and when is it justified to maintain it?","authors":"M Martínez-Sellés, F J Martín Sánchez, S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, J M Molero García, B Santiago, J A Caminero, C Barros, D García de Viedma, C Martín, E Bouza","doi":"10.37201/req/070.2023","DOIUrl":"10.37201/req/070.2023","url":null,"abstract":"<p><p>We address the advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in the current epidemiological situation in Spain and after the declaration of the World Health Organization on May 5, 2023 of the end of COVID-19 as public health emergency. We advocate for prudence and flexibility, respecting the individual decision to wear a mask and emphasizing the need for its use when symptoms suggestive of a respiratory infection appear, in situations of special vulnerability (such as immunosuppression), or when caring for patients with those infections. At present, given the observed low risk of severe COVID-19 and the low transmission of other respiratory infections, we believe that it is disproportionate to maintain the mandatory use of masks in a general way in health centers and nursing homes. However, this could change depending on the results of epidemiological surveillance and it would be necessary to reconsider returning to the obligation in periods with a high incidence of respiratory infections.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/17/revespquimioter-36-466.PMC10586740.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9689118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}